Post-market Safety and Effectiveness of the CORUS-LX System in Improving Lumbar Interbody Fusion Outcomes

计划入组 250 人 · 首次发布于 2025 年 10 月 30 日

A Phase I Study of LX-039 Tablets

计划入组 44 人 · 首次发布于 2019 年 9 月 20 日

RAPID: Phase 2 Platform Trial Of Promising Drugs For AYA Patients With R/R Ewing Sarcoma & DSRCT

计划入组 120 人 · 首次发布于 2026 年 8 月 24 日

LX-103

LX-102

LX-086

Ryder System

United States

GOSHEN HEALTH SYSTEM

United States

MEMORIAL HEALTHCARE SYSTEM

United States

Providence Medical Technology Launches Superiority Trial for CORUS-LX Lumbar Fusion System

TolerogenixX Completes Last Patient Transplant in Phase IIb TOL-2 Trial of MIC-Lx, a First-in-Class Immune Tolerance Cell Therapy for Kidney Transplantation

Lirum Therapeutics' LX-101 Shows Promising Preclinical Activity in Ewing Sarcoma, Advances to RAPID Platform Trial